Αρχική World News Merging the Histologic and Molecular Data Into an Integrated Score Significantly Improves...

Merging the Histologic and Molecular Data Into an Integrated Score Significantly Improves Precision in Stratification of Meningiomas

Retrospectively and prospectively validated data from a multicentre retrospective analysis allowed to the German Consortium on Aggressive Meningiomas researchers to devise and validate an integrated score that leverages the advantages of WHO grading, specific copy-number variations (CNVs), and methylation-based classifications. Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grades 1 and 2 meningiomas. Dr. Felix Sahm of the Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research, German Cancer Research Centre in Heidelberg, Germany and colleagues, who derived a comprehensive grading algorithm that provides most accurate prediction for individual patients with meningioma, published their findings on 7 October 2021 in the Journal of Clinical Oncology.

The authors wrote in the study background that meningiomas are the most frequent primary intracranial tumours. Patient outcome varies widely from benign to highly aggressive. However, only biomarkers for highly aggressive meningioma are established, whereas no molecularly based stratification exists for the patients with low- and intermediate-risk meningioma. In particular, TERT promoter mutation or homozygous deletion of CDKN2A/B is included in the 2021 WHO classification as independent criteria of WHO grade 3 meningioma. However, the most pressing clinical need is not to identify high-grade meningioma, but to distinguish patients with low from those with intermediate risk of recurrence.

The WHO classification of meningiomas stratifies patient cohorts into three groups with low to high risk of progression. Various approaches to increase risk prediction accuracy for individual patients with meningioma exist. CNVs are enriched in aggressive meningiomas, and methylation-based classification was introduced as a novel tool for meningioma stratification. Yet, these approaches lack comprehensive validation and integration into one unified classification concept, preventing their routine application.

The German Consortium on Aggressive Meningiomas investigators generated DNA methylation data and copy-number information for 3,031 meningiomas from 2,868 patients, and mutation data for 858 samples. They analyzed DNA methylation subgroups, CNVs, mutations, and WHO grading. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 cases.

Compared with the WHO classification, CNV and methylation subgrouping independently resulted in increased prediction accuracy of risk of recurrence. Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy. This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (p = 0.005).

Besides the overall stratification advantage, the integrated score separated more precisely for risk of progression at the diagnostically challenging interface of WHO grades 1 and 2 tumours with hazard ratios of 4.34 and 3.34 in retrospective and prospective validation cohorts.

The authors concluded that integrated molecular-morphologic score has immediate effect on risk stratification for a substantial number of patients and holds potential to transform the work-up of diagnostic meningioma samples similar to the way on how molecular profiling has changed assessment and treatment decisions for parenchymal brain tumours.

The study was supported by the Else Kröner Fresenius Foundation, the German Cancer Aid, and the Hertie Foundation.

Reference

Maas SLN, Stichel D, Hielscher T, et al. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. JCO; Published online 7 October 2021. DOI: 10.1200/JCO.21.00784.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...